Cryoport (NASDAQ:CYRX) Price Target Raised to $11.00 at UBS Group

Cryoport (NASDAQ:CYRX - Get Free Report) had its target price upped by equities research analysts at UBS Group from $10.00 to $11.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's target price indicates a potential upside of 102.21% from the stock's current price.

A number of other equities analysts have also recently commented on the company. Guggenheim assumed coverage on Cryoport in a report on Thursday, December 19th. They set a "buy" rating and a $11.00 target price for the company. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Cryoport in a research report on Monday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.83.

Cryoport Trading Down 11.7 %

CYRX stock traded down $0.72 during mid-day trading on Tuesday, hitting $5.44. 441,413 shares of the company were exchanged, compared to its average volume of 537,608. The business has a fifty day simple moving average of $6.50 and a 200-day simple moving average of $7.26. The firm has a market capitalization of $271.51 million, a P/E ratio of -1.61 and a beta of 1.67. Cryoport has a 12-month low of $4.58 and a 12-month high of $20.11. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Remove Ads

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same quarter last year, the business posted ($0.29) EPS. On average, equities research analysts predict that Cryoport will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Cryoport

In related news, CEO Jerrell Shelton sold 4,620 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 19,830 shares of company stock valued at $118,353 in the last quarter. Corporate insiders own 10.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its position in shares of Cryoport by 0.4% during the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock worth $3,012,000 after purchasing an additional 1,512 shares during the last quarter. Rhumbline Advisers boosted its holdings in Cryoport by 2.9% in the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock valued at $492,000 after acquiring an additional 1,764 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Cryoport by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after purchasing an additional 2,120 shares during the period. Nebula Research & Development LLC increased its position in shares of Cryoport by 21.6% in the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock worth $97,000 after acquiring an additional 2,207 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Cryoport by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company's stock valued at $3,144,000 after purchasing an additional 2,226 shares during the period. Institutional investors and hedge funds own 92.90% of the company's stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.